Corticosteroid Ointment Recalled Due to Bacterial Contamination
To date, the Company has not received reports of adverse events related to this recall.
Pruritus
Cibinqo Approved for Refractory, Moderate to Severe Atopic Dermatitis
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Aesthetic Treatments for Post-Cancer Care
Cancer therapies have benefits beyond simple cosmetic repairs, with significant influence on patient outcomes that improve quality of life in many domains including physical, emotional, and social.
Adbry Approved for Moderate to Severe Atopic Dermatitis
The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD.
Phase 2 STELABEC Trial Supports Ustekinumab for the Treatment of Behçet Disease
The safety and efficacy of ustekinumab was determined in a phase 2 trial for the treatment of recurrent oral ulcers in Behçet disease.
Treatment Options for Telangiectasias, Reticular Veins
The effects of various therapies for telangiectasias and reticular veins are reviewed.
Trust Your Gut: Diagnosis and Treatment of Keto Rash
Author reviews a case of prurigo pigmentosa in a patient following the ketogenic diet and outlines a strategy to diagnose and treat this condition.
Upadacitinib, Topical Corticosteroid Well Tolerated for Long-Term Atopic Dermatitis Treatment
A novel study reports the efficacy and safety of upadacitinib and topical corticosteroid through 52 weeks for the treatment of atopic dermatitis.
Tralokinumab Plus Topical Corticosteroids an Option for Severe Refractory AD
The efficacy and safety of tralokinumab plus topical corticosteroids in adult patients with inadequately controlled severe atopic dermatitis (AD) is assessed.
- Loading...
Loading...
Next post in Dermatitis
Loading... 
Loading...